Cetuximab in combination therapy: From bench to clinic

Cancer and Metastasis Reviews

Volumn 29, Issue 1, 2010, Pages 171-180

  Gerber, David E ^a   Choy, Hak ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cetuximab; Colorectal cancer; Head and neck cancer; Lung cancer; Monoclonal antibodies; Targeted therapy

Indexed keywords

BIOLOGICAL MARKER; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB;

ADVANCED CANCER; ANGIOGENESIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; COLORECTAL CANCER; CYTOTOXICITY; DNA REPAIR; DRUG EFFICACY; DRUG SAFETY; GROWTH INHIBITION; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; INOPERABLE CANCER; LOADING DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RADIATION DOSE; REVIEW; SALVAGE THERAPY; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; GENES, ERBB-1; HUMANS; NEOPLASMS;

EID: 77349118230     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-010-9215-6     Document Type: Review

References (79)

1. RV Lord J Brabender D Gandara, et al. 2002 Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer Clinical Cancer Research 8 2286 2291 12114432
2. R Rosell M Taron A Barnadas, et al. 2003 Nucleotide excision repair pathways involved in cisplatin resistance in non-small-cell lung cancer Cancer Control 10 297 305 12915808
3. F Michor MA Nowak Y Iwasa 2006 Evolution of resistance to cancer therapy Current Pharmaceutical Design 12 261 271 10.2174/138161206775201956 16454743
4. KA Olaussen A Dunant P Fouret, et al. 2006 DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy New England Journal of Medicine 355 983 991 10.1056/NEJMoa060570 16957145 (Pubitemid 44343542)
5. A Handra-Luca J Hernandez G Mountzios, et al. 2007 Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma Clinical Cancer Research 13 3855 3859 10.1158/1078-0432.CCR-07-0252 17606717 (Pubitemid 47037591)
6. CG Willett Y Boucher E di Tomaso, et al. 2004 Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nature Medicine 10 145 147 10.1038/nm988 14745444 (Pubitemid 38524883)
7. PV Dickson JB Hamner TL Sims, et al. 2007 Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy Clinical Cancer Research 13 3942 3950 10.1158/1078-0432.CCR-07-0278 17606728 (Pubitemid 47037602)
8. RS Herbst DM Shin 2002 Monoclonal antibodies to target epidermal growth factor receptor-positive tumors. A new paradigm for cancer therapy Cancer 94 1593 1611 10.1002/cncr.10372 11920518 (Pubitemid 34212655)
9. Y Yarden 2001 The EGFR family and its ligands in human cancer: Signalling mechanisms and therapeutic opportunities European Journal of Cancer 37 S3 S8 10.1016/S0959-8049(01)00230-1 11597398
10. S Haupt M Berger Z Goldberg, et al. 2003 Apoptosis-The p53 network Journal of Cell Science 116 4077 4085 10.1242/jcs.00739 12972501 (Pubitemid 37337082)
11. XH Peng P Karna Z Cao, et al. 2006 Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor 1a signal pathways increases resistance to apoptosis by up-regulating survivin gene expression Journal of Biological Chemistry 281 25903 25914 10.1074/jbc.M603414200 16847054 (Pubitemid 44401796)
12. C Kari TO Chan R Rocha de Quadros, et al. 2003 Targeting the epidermal growth factor receptor in cancer: Apoptosis takes center stage Cancer Research 63 1 5 12517767
13. HP Rodemann K Dittmann M Toulany 2007 Radiation-induced EGFR-signaling and control of DNA-damage repair International Journal of Radiation Biology 83 781 791 10.1080/09553000701769970 18058366 (Pubitemid 350219102)
14. H Sunada BE Magun J Mendelsohn, et al. 1986 Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation Proceedings of the National Academy of Sciences of the United States of America 83 3825 3829 10.1073/pnas.83.11.3825 2424012
15. ML Jaramillo Z Leon S Grothe, et al. 2006 Effect of the anti-receptor ligand-blocking 225 monoclonal antibody of EGF receptor endocytosis and sorting Experimental Cell Research 312 2778 2790 10.1016/j.yexcr.2006.05.008 16806168 (Pubitemid 44246936)
16. M Prewett P Rockwell C Rose, et al. 1996 Anti-tumor and cell cycle responses in KB cells treated with a chimeric anti-EGFR monoclonal antibody in combination with cisplatin International Journal of Oncology 9 217 224
17. J Mendelson 1997 Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy Clinical Cancer Research 3 2703 2707
18. RC Lilenbaum 2006 The evolving role of cetuximab in non-small cell lung cancer Clinical Cancer Research 12 suppl 4432s 4435s 10.1158/1078-0432.CCR-06- 0097 16857823 (Pubitemid 44197194)
19. H Kimura K Sakai T Arao, et al. 2007 Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor Cancer Science 98 1275 1280 10.1111/j.1349-7006.2007. 00510.x 17498200 (Pubitemid 46993549)
20. J Kurai H Chikumi K Hashimoto, et al. 2007 Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines Clinical Cancer Research 13 1552 1561 10.1158/1078-0432.CCR-06-1726 17332301 (Pubitemid 46450447)
21. DJ Chen CS Nirodi 2007 The epidermal growth factor receptor: A role in repair of radiation-induced DNA damage Clinical Cancer Research 13 22 Pt 1 6555 6560 10.1158/1078-0432.CCR-07-1610 18006754 (Pubitemid 350206788)
22. G Giaccone RS Herbst C Manegold, et al. 2004 Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer Journal of Clinical Oncology 22 777 784 10.1200/JCO.2004.08.001 14990632 (Pubitemid 41103588)
23. RS Herbst G Giaccone JH Schiller, et al. 2004 Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2 Journal of Clinical Oncology 22 785 794 10.1200/JCO.2004.07. 215 14990633 (Pubitemid 41103589)
24. RS Herbst D Prager R Hermann, et al. 2005 TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer Journal of Clinical Oncology 23 5892 5899 10.1200/JCO.2005.02.840 16043829 (Pubitemid 46300205)
25. U Gatzemeier A Pluzanska A Szczesna E Kaukel, et al. 2007 Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva lung cancer investigation trial Journal of Clinical Oncology 25 1545 1552 10.1200/JCO.2005.05.1474 17442998 (Pubitemid 46733081)
26. R Pirker A Pereira A Szczesna J von Pawel, et al. 2009 Cetuximab plus chemotherapy in patients with advanced non-small cell lung cancer (FLEX): An open-label randomized phase III trial Lancet 373 1525 1531 10.1016/S0140- 6736(09)60569-9 19410716
27. J Crawford AB Sandler LA Hammond, et al. 2004 ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC) [Meeting Abstracts] Journal of Clinical Oncology 22 7083
28. M Benhar D Engelberg A Levitzki 2002 Cisplatin-induced activation of the EGF receptor Oncogene 21 8723 8731 10.1038/sj.onc.1205980 12483525 (Pubitemid 36132393)
29. M Sumitomo T Asano J Asakuma T Asano A Horiguchi M Hayakawa 2004 ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway Clinical Cancer Research 10 794 801 10.1158/1078-0432.CCR-0948-03 14760103 (Pubitemid 38174018)
30. W-P Tsang S-K Kong T-T Kwok 2006 Epidermal growth factor induction of resistance to topoisomerase II toxins in human squamous carcinoma A431 cells Oncology Reports 16 789 793 16969495
31. S-M Huang JM Bock PM Harari 1999 Epidermal growth factor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck Cancer Research 59 1935 1940 10213503
32. B Vincenzi G Schiavon M Silletta D Santini G Tonini 2008 Critical Reviews in Oncology/Hematology 68 93 106 10.1016/j.critrevonc.2008.07.006 18676156
33. AMV Petit J Rak M-C Hung, et al. 1997 Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo American Journal of Pathology 151 1523 1530 9403702
34. P Perrotte T Matsumoto K Inoue, et al. 1999 Anti-epidermal growth factor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice Clinical Cancer Research 5 257 264 10037173
35. MC Prewett AT Hooper R Bassi, et al. 2002 Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts Clinical Cancer Research 8 994 1003 12006511
36. D Balin-Gauthier JP Delord P Rochaix, et al. 2006 In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR Cancer Chemotherapy and Pharmacology 57 709 718 10.1007/s00280-005-0123-3 16320055
37. F Ciardiello R Bianco V Damiano, et al. 1999 Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225 Clinical Cancer Research 5 909 916 10213228
38. S Kim CN Prichard MN Younes, et al. 2006 Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice Clinical Cancer Research 12 600 607 10.1158/1078-0432.CCR-05-1325 16428506 (Pubitemid 43166155)
39. P Steiner C Joynes R Bassi, et al. 2007 Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor Clinical Cancer Research 13 1540 1551 10.1158/1078-0432.CCR-06-1887 17332300 (Pubitemid 46450446)
40. K Inoue JW Slaton P Perrotte, et al. 2000 Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma Clinical Cancer Research 6 4874 4884 11156247 (Pubitemid 32110432)
41. D Balin-Gauthier JP Delord MJ Pillaire, et al. 2008 Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation British Journal of Cancer 98 120 128 10.1038/sj.bjc.6604134 18182978
42. M Prewett DS Deevi R Bassi, et al. 2007 Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab Clinical Cancer Research 13 7432 7440 10.1158/1078-0432.CCR-07- 1768 18094427
43. RK Schmidt-Ullrich KC Valerie W Chan, et al. 1994 Altered expression of epidermal growth factor receptor and estrogen receptor in MCF-7 cells after single and repeated radiation exposures International Journal of Radiation Oncology, Biology, Physics 29 813 819 8040028
44. RK Schmidt-Ullrich RB Mikkelsen P Dent, et al. 1997 Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation Oncogene 15 1191 1197 10.1038/sj.onc.1201275 9294612
45. JN Contessa J Hampton G Lammering, et al. 2002 Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells Oncogene 21 4032 4041 10.1038/sj.onc.1205500 12037685 (Pubitemid 34679244)
46. K Dittmann C Mayer B Fehrenbacher, et al. 2005 Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase Journal of Biological Chemistry 280 31182 31189 10.1074/jbc.M506591200 16000298 (Pubitemid 41291855)
47. PM Harari S-M Huang 2001 Head and neck cancer as a clinical model for molecular targeting of therapy: Combining EGFR blockade with radiation International Journal of Radiation Oncology, Biology, Physics 49 427 433 10.1016/S0360-3016(00)01488-7 11173137 (Pubitemid 32120240)
48. S-M Huang PM Harari 2000 Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis Clinical Cancer Research 6 2166 2174 10873065
49. D Cunningham Y Humblet S Siena, et al. 2004 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer New England Journal of Medicine 351 337 345 10.1056/NEJMoa033025 15269313 (Pubitemid 38944402)
50. Van Cutsem, E., Lang, I., D'haens, G., et al. (2008) KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. Journal of Clinical Oncology, 26, Abstract 2.
51. C Bokemeyer I Bondarenko A Makhson, et al. 2009 Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer Journal of Clinical Oncology 27 663 671 10.1200/JCO.2008.20.8397 19114683
52. JB Vermorken R Mesia F Rivera, et al. 2008 Platinum-based chemotherapy plus cetuximab in head and neck cancer New England Journal of Medicine 359 1116 1127 10.1056/NEJMoa0802656 18784101
53. J Souglakos A Kalykaki L Vamvakas, et al. 2007 Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy Annals of Oncology 18 305 310 10.1093/annonc/mdl392 17079693 (Pubitemid 46323098)
54. JB Vermorken RS Herbst X Leon, et al. 2008 Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies Cancer 112 2710 2719 10.1002/cncr.23442 18481809 (Pubitemid 351969215)
55. X León R Hitt M Constenia, et al. 2005 A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy Clinical Oncology (Royal College of Radiologists) 17 418 424
56. ®) in combination with taxane/carboplatin versus taxane/carboplatin alone as first-line treatment for patients with advanced/metastatic non-small cell lung cancer (NSCLC): B3-03 Journal of Thoracic Oncology 2 suppl 4 S340 S341 10.1097/01.JTO.0000283155. 03863.e7
57. TJ Lynch T Patel L Dreisbach, et al. 2008 Overall survival (OS) results from the phase III trial BMS 099: Cetuximab+taxane/carboplatin as 1st-line treatment for advanced NSCLC Journal of Thoracic Oncology 3 S305 10.1097/JTO.0b013e318174e9d3 (Pubitemid 351786739)
58. JA Bonner PM Harari J Giralt, et al. 2006 Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck New England Journal of Medicine 354 567 578 10.1056/NEJMoa053422 16467544 (Pubitemid 43209104)
59. JJ Caudell SM Sawrie SA Spencer, et al. 2008 Locoregionally advanced head and neck cancer treated with primary radiotherapy: A comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment International Journal of Radiation Oncology, Biology, Physics 71 676 681 18355979
60. GR Blumenschein R Paulus WJ Curran, et al. 2008 A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (pts) with stage IIIA/B non-small cell lung cancer (NSCLC): A report of the 2 year and median survival (MS) for the RTOG 0324 trial Journal of Clinical Oncology 26 May 20 suppl 7516
61. J Tabernero P Pfeiffer A Cervantes 2008 Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: An effective, more convenient alternative to weekly administration? The Oncologist 13 113 119 10.1634/theoncologist.2007-0201 18305055 (Pubitemid 351342574)
62. P Martín-Martorell S Roselló E Rodríguez-Braun, et al. 2008 Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: Results of a phase II single institution trial British Journal of Cancer 99 455 458 10.1038/sj.bjc.6604530 18665167
63. P Pfeiffer D Nielsen J Bjerregaard, et al. 2008 Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin, and 5-fluorouracil Annals of Oncology 19 1141 1145 10.1093/annonc/mdn020 18281264 (Pubitemid 351796340)
64. D Raben B Helfrich DC Chan, et al. 2005 The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer Clinical Cancer Research 11 795 805 15701870
65. KY Chung J Shia NE Kemeny, et al. 2005 Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry Journal of Clinical Oncology 23 1803 1810 10.1200/JCO.2005.08.037 15677699 (Pubitemid 46211358)
66. CD Thienelt PA Bunn Jr N Hanna, et al. 2005 Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer Journal of Clinical Oncology 23 8786 8793 10.1200/JCO.2005.03.1997 16246975 (Pubitemid 46211524)
67. F Robert G Blumenschein RS Herbst, et al. 2005 Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer Journal of Clinical Oncology 23 9089 9096 10.1200/JCO.2004.00.1438 16301597 (Pubitemid 46264008)
68. K Kelly RS Herbst JJ Crowley, et al. 2006 Concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in advanced non-small cell lung cancer (NSCLC): A randomized phase II selectional trial SWOG 0342 Journal of Clinical Oncology 24 18S 7015
69. R Rosell G Robinet A Szczesna, et al. 2008 Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer Annals of Oncology 19 362 369 10.1093/annonc/mdm474 17947225 (Pubitemid 351201721)
70. S Khambata-Ford C Harbison L Hart, et al. 2008 K-Ras mutations (mt) and EGFR-related markers as potential predictors of cetuximab benefit in 1st line advanced NSCLC: Results from the BMS099 study [abstract] Journal of Thoracic Oncology 3 Suppl. 4 S304
71. CS Karapetis S Khambata-Ford DJ Jonker, et al. 2008 K-ras mutations and benefit from cetuximab in advanced colorectal cancer New England Journal of Medicine 359 1757 1765 10.1056/NEJMoa0804385 18946061
72. S Khambata-Ford CR Garrett NJ Meropol, et al. 2007 Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab Journal of Clinical Oncology 25 3230 3237 10.1200/JCO.2006.10.5437 17664471 (Pubitemid 47325606)
73. K Yonesaka K Zejnullahu N Lindeman, et al. 2008 Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers Clinical Cancer Research 14 6963 6973 10.1158/1078-0432.CCR- 08-0957 18980991
74. F Di Nicolantonio M Martini F Molinari, et al. 2008 Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer Journal of Clinical Oncology 26 5705 5712 10.1200/JCO.2008.18.0786 19001320
75. F Bibeau E Lopez-Crapez F Di Fiore, et al. 2009 Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan Journal of Clinical Oncology 27 1122 1129 10.1200/JCO.2008.18. 0463 19164213
76. RJ Taylor SL Chan A Wood, et al. 2009 FcγRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck Cancer Immunology, Immunotherapy 58 997 1006 10.1007/s00262-008-0613-3 18979096
77. PA Philip J Benedetti C Fenoglio-Preiser, et al. 2007 Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study Journal of Clinical Oncology 25 18S LBA4509
78. K Horisberger A Treschl S Mai, et al. 2009 Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: Results of a phase II MARGIT trial International Journal of Radiation Oncology, Biology, Physics 74 1487 1493 19131187
79. J Tol M Koopman A Cats, et al. 2009 Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer New England Journal of Medicine 360 563 572 10.1056/NEJMoa0808268 19196673